Table 2. Studies for the use of non-fasting TG and remnant cholesterol levels as predictors of CVD events.
Primary endpoint | Sample size | Primary endpoint Hazard ratio (95% CI) | |
---|---|---|---|
Varbo et al.16) | Incidence of CVD with 88.41 mg/dL increase in non-fasting remnant cholesterol | 73513 | 1.4 (1.3-1.5) |
Nordestgaard et al.27) | Incident MI, CVD, and death with 88.41 mg/dL increase in non-fasting TG | 13981 | Men 1.14 (1.10-1.19) Women 1.30 (1.22-1.40) |
The Women's Health Study28) | Incident CVD, non-fatal MI, non-fatal stroke, coronary revascularization or cardiovascular death | 26509 | 2.53 (1.69-3.79) |
Jørgensen et al.30) | Incidence of MI with genetically elevated doubling of non-fasting TG and remnant cholesterol | 10391 | 1.87 (1.25-2.81) |
TG: triglyceride, CVD: cardiovascular disease, CI: confidence interval, MI: myocardial infarction